{"id":794889,"date":"2024-12-13T16:33:43","date_gmt":"2024-12-13T21:33:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/"},"modified":"2024-12-13T16:33:43","modified_gmt":"2024-12-13T21:33:43","slug":"medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/","title":{"rendered":"MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>Pre-Money Valuation of JPY9 Billion is Approximately Multiples of Current Parent Company Market Capitalization.<\/li>\n<li style=\"text-align:justify\">Strategic Investors Further Validation of Technology and Growth Potential.<\/li>\n<li style=\"text-align:justify\">Further Commercialization with Recent 25,000 Unit Order from B2B Sales Channel.<\/li>\n<\/ul>\n<p>TOKYO, Dec.  13, 2024  (GLOBE NEWSWIRE) &#8212; MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] million calculated at an exchange rate of JPY[153.64] to US$1) at a pre-money equity valuation of JPY9 billion (approximately USD $ [58.6] million calculated at an exchange rate of JPY[153.64] to US$1) in its Series A equity financing. NFES Technologies Inc. is the lead investor in the financing round, and several public companies in Japan, including M3, Inc. (TOKYO PRIME: 2413) and Elematec Corporation (TOKYO PRIME: 2715), as well as certain individual investors are also participating. The Series A equity financing round is still ongoing. MEDIROM MOTHER Labs has closed financings with six investors to date and intends to conclude the financing round by December 31, 2024. <\/p>\n<p>\u201cWe are very excited that our MEDIROM MOTHER Labs subsidiary has received such significant validation from strategic partners as our lead investor NFES Technologies Inc. as well as M3,Inc and Elematec Corporation. The pre money valuation of 9 billion yen is approximately multiples of MEDIROM\u2019s current NASDAQ listing market capitalization which I believe further validates our technology, business model and growth potential.\u201d said Kouji.<\/p>\n<p>The MOTHER Bracelet<sup>\u00ae<\/sup> is currently in commercialization. From July 1, 2024 through October 31, 2024, MEDIROM MOTHER Labs received purchase orders for an aggregate of over 25,000 units from its B2B sales channel. \u201cWe believe the MOTHER Bracelet<sup>\u00ae<\/sup> to be the world\u2019s first fitness tracker that requires no electric charging by utilizing an innovative technology that enables the user\u2019s body heat to generate electricity. We co-developed it with Matrix Industries, based in Silicon Valley and believe its features are cutting-edge technology with rich features and ease of use to track fitness levels, sleep patterns, pulse and body temperature We will continue to target markets such as hospitals, nursing homes and gyms, where such data is vital,\u201d said Yoshio Uekusa, CEO of MEDIROM MOTHER Labs.<\/p>\n<p>\n        <strong>ABOUT MEDIROM MOTHER Labs Inc.<\/strong><br \/>\n        <br \/>A subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (\u201cMEDIROM\u201d), MEDIROM Mother Labs Inc. focuses on the health-tech sector. The company\u2019s core activities include the &#8220;Specific Health Guidance Program&#8221; offered through the &#8220;Lav&#8221; health application and development and sales of the 24\/7 recharge-free MOTHER Bracelet<sup>\u00ae\ufe0e<\/sup> smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet<sup>\u00ae\ufe0e<\/sup>, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, and similar industries.<\/p>\n<p>\n        <strong>Forward-Looking Statements Regarding MEDIROM and MOTHER Labs<\/strong>\n      <\/p>\n<p>Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM\u2019s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cdesign,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201chope,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201cgoal,\u201d or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM\u2019s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM\u2019s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM\u2019s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM\u2019s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM\u2019s operations, results of operations, growth strategy and liquidity. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">MEDIROM\u2019s ability to achieve its development goals for its business and execute and evolve its growth strategies, priorities and initiatives;<\/li>\n<li style=\"text-align:justify\">MEDIROM Mother Labs\u2019s ability to close its Series A equity financing on the anticipated timeline or at all;<\/li>\n<li style=\"text-align:justify\">MEDIROM\u2019s ability to collaborate in the anticipated manner;<\/li>\n<li style=\"text-align:justify\">changes in Japanese and global economic conditions and financial markets, including their effects on MEDIROM\u2019s expansion in Japan and certain overseas markets;<\/li>\n<li style=\"text-align:justify\">MEDIROM\u2019s ability to increase sales of the MOTHER Bracelet and achieve and sustain profitability in its Digital Preventative Healthcare Segment;<\/li>\n<li style=\"text-align:justify\">the fluctuation of foreign exchange rates, which affects MEDIROM\u2019s expenses and liabilities payable in foreign currencies;<\/li>\n<li style=\"text-align:justify\">MEDIROM\u2019s ability to maintain and enhance the value of its brands and to enforce and maintain its trademarks and protect its other intellectual property;<\/li>\n<li style=\"text-align:justify\">MEDIROM\u2019s ability to raise additional capital on acceptable terms or at all;<\/li>\n<li style=\"text-align:justify\">MEDIROM\u2019s level of indebtedness and potential restrictions on MEDIROM under MEDIROM\u2019s debt instruments;<\/li>\n<li style=\"text-align:justify\">changes in consumer preferences and MEDIROM\u2019s competitive environment;<\/li>\n<li style=\"text-align:justify\">MEDIROM\u2019s ability to respond to natural disasters, such as earthquakes and tsunamis, and to global pandemics, such as COVID-19; and<\/li>\n<li style=\"text-align:justify\">the regulatory environment in which MEDIROM operates.<\/li>\n<\/ul>\n<p>More information on these risks and other potential factors that could affect MEDIROM\u2019s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), including in the \u201cRisk Factors\u201d and \u201cOperating and Financial Review and Prospects\u201d sections of MEDIROM\u2019s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.<\/p>\n<p>\n        <strong>MEDIROM Healthcare Technologies Inc.<\/strong><br \/>\n        <br \/>NASDAQ Symbol: MRM<br \/>Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan<br \/>Web <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cP5P3XyrKAu6vrnuAYnREF03FhNW6eLC5xLT88IIe4-wPnKJR88GRxxDHA63iCjUhnuZkdiuV_WUOpgcf_6Qhn-q_ad7s27yqqx62pO55hE=\" rel=\"nofollow\" target=\"_blank\">https:\/\/medirom.co.jp\/en<br \/><\/a><\/u>Contact: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IRUMuT7BGw5MyFSaL3nUYK-DAr62R1TiORBzIPRsJoQIbb2JqQmkhEd4nDHMm3b8yxNJxs153r1D8-qSOcAeJA==\" rel=\"nofollow\" target=\"_blank\">ir@medirom.co.jp<\/a><\/p>\n<p>\n        <strong>MEDIROM MOTHER Labs Inc.<\/strong><br \/>\n        <br \/>Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan<\/p>\n<p>For more information visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cP5P3XyrKAu6vrnuAYnREJkoG0yzQsE6jHFQBORf6qT-UkuYyyO26jYN5cE-qZn7O2opjC8fQ9PqPMZnBuG-vYlizrebgJNtZ1L06bza81s=\" rel=\"nofollow\" target=\"_blank\">https:\/\/mother-bracelet.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODk3OCM2NjM2NTg2IzIyNTI5NTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzQ5MjQ3ODItYzcyOS00NDBkLWIzNzctYmU2MGRmYjQzNzRmLTEyNjQ1MDQ=\/tiny\/MEDIROM-Healthcare-Technologie.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pre-Money Valuation of JPY9 Billion is Approximately Multiples of Current Parent Company Market Capitalization. Strategic Investors Further Validation of Technology and Growth Potential. Further Commercialization with Recent 25,000 Unit Order from B2B Sales Channel. TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) &#8212; MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] million calculated at an exchange rate of JPY[153.64] to US$1) at a pre-money equity valuation of JPY9 billion (approximately USD $ [58.6] million calculated at an exchange rate of JPY[153.64] to US$1) in its Series A equity financing. NFES Technologies Inc. is the lead investor in the financing round, and several &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-794889","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Pre-Money Valuation of JPY9 Billion is Approximately Multiples of Current Parent Company Market Capitalization. Strategic Investors Further Validation of Technology and Growth Potential. Further Commercialization with Recent 25,000 Unit Order from B2B Sales Channel. TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) &#8212; MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] million calculated at an exchange rate of JPY[153.64] to US$1) at a pre-money equity valuation of JPY9 billion (approximately USD $ [58.6] million calculated at an exchange rate of JPY[153.64] to US$1) in its Series A equity financing. NFES Technologies Inc. is the lead investor in the financing round, and several &hellip; Continue reading &quot;MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-13T21:33:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODk3OCM2NjM2NTg2IzIyNTI5NTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round\",\"datePublished\":\"2024-12-13T21:33:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/\"},\"wordCount\":1078,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODk3OCM2NjM2NTg2IzIyNTI5NTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/\",\"name\":\"MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODk3OCM2NjM2NTg2IzIyNTI5NTE=\",\"datePublished\":\"2024-12-13T21:33:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODk3OCM2NjM2NTg2IzIyNTI5NTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODk3OCM2NjM2NTg2IzIyNTI5NTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/","og_locale":"en_US","og_type":"article","og_title":"MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round - Market Newsdesk","og_description":"Pre-Money Valuation of JPY9 Billion is Approximately Multiples of Current Parent Company Market Capitalization. Strategic Investors Further Validation of Technology and Growth Potential. Further Commercialization with Recent 25,000 Unit Order from B2B Sales Channel. TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) &#8212; MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] million calculated at an exchange rate of JPY[153.64] to US$1) at a pre-money equity valuation of JPY9 billion (approximately USD $ [58.6] million calculated at an exchange rate of JPY[153.64] to US$1) in its Series A equity financing. NFES Technologies Inc. is the lead investor in the financing round, and several &hellip; Continue reading \"MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-13T21:33:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODk3OCM2NjM2NTg2IzIyNTI5NTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round","datePublished":"2024-12-13T21:33:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/"},"wordCount":1078,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODk3OCM2NjM2NTg2IzIyNTI5NTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/","name":"MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODk3OCM2NjM2NTg2IzIyNTI5NTE=","datePublished":"2024-12-13T21:33:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODk3OCM2NjM2NTg2IzIyNTI5NTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODk3OCM2NjM2NTg2IzIyNTI5NTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medirom-healthcare-technologys-subsidiary-medirom-mother-labs-raises-an-aggregate-total-of-jpy260-3-million-in-its-series-a-financing-round\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MEDIROM Healthcare Technology\u2018s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=794889"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794889\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=794889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=794889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=794889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}